APA (7th ed.) Citation

Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., . . . Weisel, K. (2024). Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial. Hematology, 29(1), 1. https://doi.org/10.1080/16078454.2024.2320006

Chicago Style (17th ed.) Citation

Salwender, Hans, et al. "Cytomegalovirus Immunoglobulin Serology Prevalence in Patients with Newly Diagnosed Multiple Myeloma Treated Within the GMMG-MM5 Phase III Trial." Hematology 29, no. 1 (2024): 1. https://doi.org/10.1080/16078454.2024.2320006.

MLA (9th ed.) Citation

Salwender, Hans, et al. "Cytomegalovirus Immunoglobulin Serology Prevalence in Patients with Newly Diagnosed Multiple Myeloma Treated Within the GMMG-MM5 Phase III Trial." Hematology, vol. 29, no. 1, 2024, p. 1, https://doi.org/10.1080/16078454.2024.2320006.